Histamine H4 receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation

被引:54
作者
Desai, Pragnya [1 ]
Thurmond, Robin L. [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA
关键词
Cytokines; Histamine; Inflammation; Mast cells; Toll-like receptors; AIRWAY INFLAMMATION; MEDIATES CHEMOTAXIS; CYTOKINE SECRETION; PHOSPHORYLATION; ANTAGONISTS; INHIBITION; KINASE; POTENT; DIFFERENTIATION; IDENTIFICATION;
D O I
10.1002/eji.201040932
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The histamine H-4 receptor (H4R) has been implicated in numerous inflammatory functions. Here it is shown that the receptor can mediate cytokine production from mast cells. Histamine and an H4R agonist, JNJ 28610244, induced the production of IL-6 in mouse bone marrow (BM)-derived mast cells. This effect was blocked by two different H4R antagonists and was not present in H4R-deficient cells. In addition, histamine acting via the H4R potentiated LPS-induced IL-6 production. Histamine-induced IL-6 production could be blocked by inhibitors of ERK and phosphoinositide 3-kinase gamma (PI3K gamma) pathways. Furthermore, it was shown that H4R activation can induce phosphorylation of ERK, MEK and AKT. H4R activation led to a rapid and transient phosphorylation of these kinases, whereas with LPS the activation occurred at later time points. When both histamine and LPS were added, the phosphorylation was evident at 5 min and persisted for at least 60 min suggesting that changes in the kinetics of kinase activation may be one mechanism driving the signaling interaction between the H4R and toll-like receptors. These observations suggest that the H4R can synergize with other inflammatory signals to potentiate cytokine production and provides mechanistic information on the role of the H4R in inflammation.
引用
收藏
页码:1764 / 1773
页数:10
相关论文
共 46 条
[1]  
Abramoff M.D., 2004, Biophotonics International, V11, P36
[2]   A new class of diamine-based human histamine H3 receptor antagonists:: 4-(aminoalkoxy)benzylamines [J].
Apodaca, R ;
Dvorak, CA ;
Xiao, W ;
Barbier, AJ ;
Boggs, JD ;
Wilson, SJ ;
Lovenberg, TW ;
Carruthers, NI .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (18) :3938-3944
[3]   The Akt/GSK-3β axis as a new signaling pathway of the histamine H3 receptor [J].
Bongers, Gerold ;
Sallmenj, Tina ;
Passani, Maria Beatrice ;
Mariottini, Chiara ;
Wendelin, Dominique ;
Lozada, Adrian ;
van Marle, Andre ;
Navis, Marjon ;
Blandina, Patrizio ;
Bakker, Remko A. ;
Panula, Pertti ;
Leurs, Rob .
JOURNAL OF NEUROCHEMISTRY, 2007, 103 (01) :248-258
[4]   Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor [J].
Buckland, KF ;
Williams, TJ ;
Conroy, DM .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (06) :1117-1127
[5]   ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence [J].
Cagnol, Sebastien ;
Chambard, Jean-Claude .
FEBS JOURNAL, 2010, 277 (01) :2-21
[6]   Histamine induces CD86 expression and chemokine production by human immature dendritic cells [J].
Caron, G ;
Delneste, Y ;
Roelandts, E ;
Duez, C ;
Herbault, N ;
Magistrelli, G ;
Bonnefoy, JY ;
Pestel, J ;
Jeannin, P .
JOURNAL OF IMMUNOLOGY, 2001, 166 (10) :6000-6006
[7]  
CARROLL MP, 1994, J BIOL CHEM, V269, P1249
[8]   Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens [J].
Chen, JR ;
Plotkin, LI ;
Aguirre, JI ;
Han, L ;
Jilka, RL ;
Kousteni, S ;
Bellido, T ;
Manolagas, SC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (06) :4632-4638
[9]   Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines [J].
Cowden, Jeffery M. ;
Riley, Jason P. ;
Ma, Jing Ying ;
Thurmond, Robin L. ;
Dunford, Paul J. .
RESPIRATORY RESEARCH, 2010, 11
[10]   The Histamine H4 Receptor Mediates Inflammation and Pruritus in Th2-Dependent Dermal Inflammation [J].
Cowden, Jeffery M. ;
Zhang, Mai ;
Dunford, Paul J. ;
Thurmond, Robin L. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (04) :1023-1033